Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02QFW
|
|||
Former ID |
DIB009096
|
|||
Drug Name |
Trofinetide
|
|||
Synonyms |
Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Rett syndrome [ICD-11: LD90.4; ICD-10: F84.2] | Approved | [1] | |
Fragile X syndrome [ICD-11: LD55; ICD-10: Q99.2] | Phase 2 | [2] | ||
Traumatic brain injury [ICD-11: NA07.Z] | Phase 2 | [3] | ||
Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 2 | [4] | ||
Company |
Acadia Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C13H21N3O6
|
|||
Canonical SMILES |
CC1(CCCN1C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O
|
|||
InChI |
1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
|
|||
InChIKey |
BUSXWGRAOZQTEY-SDBXPKJASA-N
|
|||
CAS Number |
CAS 853400-76-7
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217026. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 4 | NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.